Although biomedical devices have greatly evolved, none of the materials that have been used to date are able to meet all the hemocompatibility criteria. The rapid accumulation of proteins at the implant surface and the subsequent physiological response are the main causes of failure. Thus, the appropriate design of antithrombotic materials is of the utmost importance. In this work, we employed Carbothane® electrospun matrices (PCU) for lysine surface modification, using oligomers obtained from allyl glycidyl ether (AGE) reaction as spacers. This technique enables the binding of several lysine molecules per urethane linkage, which, along with the large surface-to-volume ratio of the electrospun membranes, leads to high ε-amino free lysine grafting (29 ± 2 nmol cm⁻²). The incorporation of AGE oligomers significantly reduced the nonspecific protein adsorption, while further modification with lysine led to a more pronounced decrease (25% for BSA, 35% for fibrinogen, and 30% for PNP proteins, with respect to PCU membranes). The lysine-modified matrices presented increased plasminogen adsorption capacity and in vitro clot lysis ability after incubation in pooled normal human plasma and tissue plasminogen activator, confirming the plasminogen adsorption selectivity and thus improving the hemocompatibility behavior of these matrices. Therefore, the obtained electrospun membranes are promising coatings for biomedical devices with fibrinolytic activity.

尽管生物医学设备已经有了很大的发展，但迄今为止使用的材料都不能满足所有的血液相容性标准。蛋白质在植入物表面的快速积累和随后的生理反应是失败的主要原因。因此，抗血栓材料的适当设计至关重要。在这项工作中，我们使用 Carbothane® 电纺基质 (PCU) 进行赖氨酸表面改性，使用从烯丙基缩水甘油醚 (AGE) 反应中获得的低聚物作为间隔物。该技术使每个氨基甲酸酯键结合几个赖氨酸分子，连同电纺膜的大表面积与体积比，导致高 ε-氨基游离赖氨酸接枝 (29 ± 2 nmol cm ^-2）。AGE 寡聚体的掺入显着降低了非特异性蛋白质吸附，而赖氨酸的进一步修饰导致更明显的降低（相对于 PCU 膜，BSA 为 25%，纤维蛋白原为 35%，PNP 蛋白为 30%）。在混合的正常人血浆和组织纤溶酶原激活剂中孵育后，赖氨酸修饰的基质表现出增加的纤溶酶原吸附能力和体外凝块溶解能力，证实了纤溶酶原吸附选择性，从而改善了这些基质的血液相容性行为。因此，获得的电纺膜是具有纤溶活性的生物医学装置的有前途的涂层。